Matt Dilmaghani

Matt Dilmaghani is an Analyst at Eversept Partners in New York City, specializing in healthcare sector investments and quantitative research. In his current role, he analyzes public and private healthcare equities, supporting portfolio construction with quantitative and risk analytics relevant to life sciences, pharmaceuticals, and healthcare services.

Previously, Matt served as Principal of Risk and Quantitative Research at Chalkstream Capital Group, focusing on alternative investments and proprietary risk management reporting for multi-asset class portfolios, including hedge fund, private equity, and credit strategies. He also has technology leadership experience as an Advisory Director and Partner at Lamprey Systems, working at the intersection of investment analytics and enterprise technology solutions.

Matt holds an MBA from the University of Pennsylvania's Wharton School and a Bachelor of Science in Engineering (Operations Management) from the University of Pennsylvania, with prior education from Choate Rosemary Hall. His expertise in quantitative analysis, risk management, and healthcare investment has contributed to improved research processes and risk frameworks within the asset management industry.